Skip to content
lifestyle.goodsciencing.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Celcuity Inc.
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
August 26, 2026
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
August 17, 2026
Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call
August 6, 2026
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
July 30, 2026
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
July 14, 2026
Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
May 15, 2026
Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients
May 14, 2026
Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call
May 8, 2026
Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call
May 8, 2026
Celcuity’s Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort
May 1, 2026
1
2
Next Page
→